Optometry Times的动态

Thoughts on this? >> Three papers on MDMA are retracted by medical journal, just a day after Lykos' FDA rejection >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #biotech #pharmaceutical

Thoughts on this? >> Three papers on MDMA are retracted by medical journal, just a day after Lykos' FDA rejection >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #productmarketing #biotech

Thrilled to be back at the BioPharmaDispatch conference! ?? The sessions were incredibly insightful, particularly the updates on the 8CPA presented by Trent Twomey and the discussions on Biosimilars led by Hayley Tamborini. It’s clear from the discussions that the absence of incentives for Biosimilar switching at both prescriber and patient levels remains a significant barrier to adoption. Looking forward to engaging more on these crucial topics! #BioPharmaDispatch2024 #Biosimilars #PharmaIndustry #CommunityPharmacy #Informacy

The identification and management of patients at high bleeding risk (HBR) undergoing TAVI are of major importance, but the lack of standardised definitions is challenging for trial design, data interpretation, and clinical decision-making. The Valve Academic Research Consortium for High Bleeding Risk (VARC-HBR) is a collaboration among leading research organisations, regulatory authorities, and physician-scientists from Europe, the USA, and Asia, with a major focus on TAVI-related bleeding. This document represents the first pragmatic approach to a consistent definition of HBR evaluating the safety and effectiveness of procedures, devices and drug regimens for patients undergoing TAVI. Philippe GAROT https://ow.ly/mYNi50S3PKh

Sarfaraz K. Niazi, PhD, has long discussed the challenges with PBMs that plague the biosimilar industry. Join us as he addresses the NYT article where the FTC exposes the middlemen keeping you from more affordable medications and the new legislation that attempts to reform their practices and encourage biosimilar adoption. https://lnkd.in/eJaJ929c

Negotiators at INC-5 are urged by the?Global Self-Care Federation, IFPMA, and the IGBA - International Generic and Biosimilar medicines Association to prioritize patient safety and accept plastic medical packaging where safe alternatives don’t yet exist Click here to read: https://lnkd.in/eUW-rV2e To get access to exclusive premium content, become a Packaging Europe member: https://lnkd.in/em_Jz4_Q Follow our hashtag to stay up to date with the latest packaging news: #PackagingEurope

The identification and management of patients at high bleeding risk (HBR) undergoing TAVI are of major importance, but the lack of standardised definitions is challenging for trial design, data interpretation, and clinical decision-making. The Valve Academic Research Consortium for High Bleeding Risk (VARC-HBR) is a collaboration among leading research organisations, regulatory authorities, and physician-scientists from Europe, the USA, and Asia, with a major focus on TAVI-related bleeding. This document represents the first pragmatic approach to a consistent definition of HBR evaluating the safety and effectiveness of procedures, devices and drug regimens for patients undergoing TAVI. https://lnkd.in/e6Ri8Wez

Exciting news! Join us at Pharma Forum March 24-27, in Tampa, Florida. Pharma Forum is the premier conference for meeting and event professionals shaping the future of medical meetings and compliance strategies. If you're headed to Pharma Forum, stop by and visit us at booth number 303. We can't wait to connect with you! #PharmaForum #InnovateComplyConnect #MedicalMeetings #TampaFlorida #Booth303 #SeeYouThere #L!VE

Your regulatory strategy relies in part on your ability to confidently predict transporter-mediated DDIs. In this webinar, Senior Scientist Revathi chapa and Scientist II Suvarchala kiranmai Avvari Avvari will explain how to characterize and validate the effect of transporters on drug absorption, systemic distribution, and systemic clearance. They’ll share real-life case studies, highlighting how GastroPlus DDI projections have been used in lieu of clinical studies. They’ll walk you through the data and reports that can be submitted to support regulatory decision-making, increasing the likelihood of your program approval and success. https://lnkd.in/gm-yjXRu

?? We are thrilled to announce Dr. Deborah Jones, Ph.D, EMEIA Sales Director at Proveris Scientific Corporation, is an Official Speaking Partner at the 5th Annual Inhalation and Respiratory Drug Delivery Conference in Berlin, Germany, from September 18-20, 2024. ?? Join Deborah at Eurostars Berlin Luxury Class Hotel for insightful discussions on inhalation and nasal drug delivery testing solutions. PRESENTATION OVERVIEW Derisking OINDP Development: Incorporating nasal sprays, PMDIs, SMIs, and DPIs ??Understand the multifaceted interactions between patient, formulation, and device in OINDP development. ??Explore the unique development challenges of each drug type. ??Learn how to utilize knowledge and tools to gain insights and mitigate risks in product development. ?? Connect in advance of the conference: [email protected] ?? Visit the conference website: https://lnkd.in/dkTgGQFU #Proveris #Instruments #LaboratoryTestServices #OINDP #InhalerTesting #NasalSprayTesting #DrugDevelopment